Publications by authors named "J Lachaine"
Background: Bruton tyrosine kinase inhibitors (BTKis) represent an advancement in chronic lymphocytic leukemia; however, these agents are administered continuously until disease progression or unacceptable toxicity, raising concerns about their affordability. Venetoclax in combination with obinutuzumab (VO) is a fixed-duration (12-month) treatment, approved in Canada in 2020. This study estimated the total cumulative cost of different treatment sequences and evaluated the economic impact of introducing treatment sequences with/without VO, from a Canadian health care system perspective.
View Article and Find Full Text PDFBackground Acute myeloid leukemia (AML) represents a significant burden for patients and their families, and to the healthcare system. This study estimated the total cost of illness associated with newly diagnosed AML patients in Canada. Methods The economic burden of AML was estimated using an incidence-based model, analyzing different types of AML cases in Canada.
View Article and Find Full Text PDFArticle Synopsis
- - The network meta-analysis evaluated the effectiveness of combining venetoclax (VEN) with azacitidine (AZA) or low-dose cytarabine (LDAC) against other treatments and best supportive care for adults with untreated acute myeloid leukemia not eligible for intensive chemotherapy.
- - A systematic review identified five phase III trials comprising 1,140 patients, and the analysis showed that VEN + LDAC and VEN + AZA had the highest success rates for achieving complete remission and overall survival compared to other treatments.
- - The study concluded that both VEN + AZA and VEN + LDAC significantly outperformed monotherapies, suggesting these combinations should be prioritized for treatment-naive patients in this specific leukemia population.
Objective: To assess antiretroviral therapy (ART) adherence among people with HIV (PWH) in Canada and identify baseline characteristics associated with suboptimal adherence (<95%).
Design: Retrospective observational study using data from the National Prescription Drug Utilization Information System and Régie de l'assurance maladie Quebec (RAMQ) Public Prescription Drug Insurance Plan.
Methods: This analysis included PWH aged 18 years or older who initiated an ART regimen and were followed for at least 12 months (2010-2020).
Background: Continuous oral targeted therapies (OTT) represent a major economic burden on the Canadian healthcare system, due to their high cost and administration until disease progression/toxicity. The recent introduction of venetoclax-based fixed-duration combination therapies has the potential to reduce such costs. This study aims to estimate the prevalence and the cost of CLL in Canada with the introduction of fixed OTT.
View Article and Find Full Text PDF